DAIKEN MEDICAL (7775) FY2026 Q3 Earnings Report

Quick View

Executive Summary

Despite higher revenue, profit declined due to rising costs, resulting in an earnings performance characterized by revenue growth but lower profit. Revenue was ¥78.8B (+2.8% YoY), Operating Income was ¥11.2B (-15.2%), Ordinary Income was also ¥11.2B (-15.2%), and Net Income was ¥8.4B (-12.2%). The primary factor behind the decline in profit was the decrease in the gross margin to 39.0% from 42.0% in the same period of the previous year. The SG&A ratio was 24.8%, virtually unchanged, indicating that a sharp increase in SG&A expenses was not a contributing factor.

Factors Affecting Earnings

【Revenue】Revenue was ¥78.8B, representing a 2.8% year-on-year increase. However, the cost of sales increased by 8.3% year-on-year to ¥48.1B, substantially exceeding the growth in revenue.

【Profit and Loss】As the increase in the cost of sales exceeded revenue growth, gross profit decreased to ¥30.7B (¥32.2B in the previous year), and the gross margin declined by 3.1pt to 39.0% from 42.0% in the same period of the previous year. SG&A expenses remained limited to ¥19.5B (+2.5%), and the SG&A ratio of 24.8% was broadly in line with the previous year. Operating Income was ¥11.2B (-15.2%), Ordinary Income was also ¥11.2B (-15.2%), and Net Income was ¥8.4B (-12.2%). The scale of non-operating and extraordinary gains and losses was small, and the gap between Ordinary Income and Net Income was primarily attributable to the tax burden. In conclusion, the results were characterized by revenue growth but lower profit, with the increase in the cost ratio being the sole major factor.

Key Financial Indicators

【Profitability】The Operating Income margin was 14.1% (17.2% in the previous year), and the Net Income margin was 10.7% (12.5% in the previous year). Although both declined, their absolute levels remain favorable. Annualized ROE was 14.6%, while annualized ROA was approximately 10.0%, indicating that asset efficiency has been maintained.【Cash Quality】Trade receivables (accounts receivable and electronically recorded monetary claims) were ¥28.1B, up 13.8% year-on-year and exceeding revenue growth. Annualized DSO was approximately 98 days, and annualized CCC was approximately 119 days, indicating substantial funds tied up in working capital. Finished goods inventory was ¥9.7B, accounting for 66.5% of total inventory, and therefore warrants monitoring from an inventory turnover perspective.【Investment Efficiency】Interest coverage was 138.8x, indicating a negligible interest expense burden, while asset turnover was approximately 0.95x, broadly maintaining a level of around 1x.【Financial Soundness】The Equity Ratio improved to 69.3% (66.9% in the previous year), and the current ratio was 239.8%, indicating ample working capital. The interest-bearing debt-to-capital ratio was 0.44x, and the Debt/Capital ratio was 16.0%, reflecting a conservative capital structure.

Cash Flow Analysis

Although direct data from the cash flow statement is unavailable, an analysis of fund movements based on changes in the balance sheet indicates that cash and deposits decreased by ¥6.1B, from ¥30.0B in the same period of the previous year to ¥23.8B. This decrease was related to delayed collection resulting from a ¥3.4B increase in trade receivables (¥24.7B→¥28.1B), repayment of ¥2.8B in long-term borrowings, and a change in the funding structure involving a ¥2.0B increase in short-term borrowings. Annualized CCC was long at approximately 119 days, indicating that the speed at which profit was converted into cash was relatively slow despite the revenue growth. Meanwhile, investment in property, plant and equipment continued to increase (¥39.3B→¥40.1B), and the allocation of funds to investing activities is also considered to have contributed to the decrease in cash. Overall, although cash and deposits declined, the current ratio of 239.8% and the quick ratio of 239.8% remained high, and concerns regarding short-term liquidity are limited.

Quality of Earnings

Non-operating and extraordinary gains and losses during the period were immaterial: non-operating income was ¥0.1B, non-operating expenses were ¥0.1B, and extraordinary losses were ¥0.0B (loss on disposal of fixed assets), all of which were small in scale. The fact that Ordinary Income and Operating Income were both ¥11.2B indicates that temporary non-operating factors had almost no impact on earnings. Meanwhile, the difference between Ordinary Income of ¥11.2B and Net Income of ¥8.4B was primarily attributable to income taxes of ¥2.7B (effective tax rate of approximately 24.3%), with no unusual factors other than the tax burden identified. The fact that the increase in trade receivables (+13.8%) substantially exceeded revenue growth (+2.8%) warrants attention from an accruals perspective, suggesting that the increase in sales may not have been fully matched by cash collections. Overall, current-period profit reflects a recurring earnings structure with little dependence on temporary factors; however, the decline in the gross margin and deterioration in working capital are weighing on the underlying quality of earnings.

Earnings Forecasts and Guidance

The full-year company forecasts are revenue of ¥102.0B (+2.5% YoY), Operating Income of ¥12.5B (-17.3%), Ordinary Income of ¥12.5B (-17.2%), and Net Income of ¥8.8B (-19.8%). The cumulative Q3 progress ratios were 77.3% for revenue, 89.2% for Operating Income, and 95.5% for Net Income, all representing high progress above the standard 75% level. However, achieving the full-year plan implies that Q4 Operating Income will be limited to approximately ¥1.35B (profit margin of approximately 5.8%), representing a substantial decline from the cumulative Operating Income margin of 14.1%. While this indicates that the full-year plan is conservative, the extent of gross margin recovery and whether the actual Q4 profit margin will meet the planned level will be key areas of focus going forward.

Shareholder Returns

The Q2 dividend was ¥9.00 per share. The full-year dividend forecast is ¥20.00 per share, resulting in an expected Payout Ratio of approximately 65.3% against forecast full-year EPS of ¥30.63. This Payout Ratio is based solely on dividends and is slightly above the benchmark of 60%; however, given the substantial capital accumulation, including retained earnings of ¥85.9B and net assets of ¥77.0B, the sustainability of the dividend itself is supported by the capital base. No disclosure regarding share repurchases was identified, and shareholder returns are centered on dividends.

Risk Factors

1. Risk of rising costs: The cost of sales increased by 8.3% year-on-year, exceeding revenue growth of 2.8%, and the gross margin declined by 3.1pt to 39.0%. If rising costs cannot be absorbed through pricing and product mix, the decline in profit margins may continue even amid revenue growth.

2. Working capital and collection risk: Trade receivables increased by 13.8% year-on-year, while annualized DSO was approximately 98 days and annualized CCC was approximately 119 days. An increase in receivables exceeding sales growth indicates an expansion in funds tied up in working capital, and continued deterioration in collection efficiency could pressure capital efficiency.

3. Shorter-term funding structure: Long-term borrowings decreased by 33.9%, from ¥8.2B to ¥5.4B, while short-term borrowings increased by 27.8%, from ¥7.2B to ¥9.2B. Greater dependence on short-term liabilities is a factor that increases sensitivity to changes in refinancing conditions.

Industry Benchmark (For Reference; Company Research)

Industry Benchmark (manufacturing)

Profitability and Returns

The Company's Operating Income margin and Net Income margin both substantially exceed the industry median, placing its profitability among the higher levels within the industry.

Growth and Capital Efficiency

The revenue growth rate was slightly below the industry median, placing the Company's growth broadly at an industry-standard level.

※Source: Company research

Key Takeaways from the Results

1. Despite revenue growth, the gross margin declined by 3.1pt, resulting in double-digit declines in both Operating Income and Net Income. This highlights the impact of changes in the cost structure on the quality of earnings. The Net Income margin of 10.7% and annualized ROE of 14.6% remained at favorable levels compared with the industry.

2. The increase in trade receivables (+13.8%) exceeded revenue growth (+2.8%), and annualized CCC reached approximately 119 days. This is a structural point of observation indicating that the increase in revenue may not have been sufficiently translated into cash collections.

3. Progress against the full-year plan was high, at 89.2% for Operating Income and 95.5% for Net Income. However, the plan assumes that the Q4 profit margin will be substantially lower than the cumulative actual margin, making the actual composition of full-year results an item to monitor going forward.

Theoretical Share Price (Reference Value)

Sensitivity: ¥274–¥289 at ±1% for the cost of equity, and ¥281–¥281 at ±0.1 for ω.

Notes:

• Because the progress of Net Income against the full-year forecast (95%) exceeds the standard level (75%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies with progress ahead of schedule tend to exceed forecasts; adjustments may be excessive for businesses with strong seasonality).
• Net assets as of the quarter-end are used (there is a timing gap with the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated at a somewhat elevated level.

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, consulting a professional as necessary.

---End of Report---